
The Neo-AEGIS study compared trimodality therapy with preoperative radiotherapy (CROSS regimen) to perioperative chemotherapy regimens (predominantly modified MAGIC regimen) in adenocarcinoma of the oesophagus and oesophagogastric junction. The study included 362 patients and closed early in December 2020. Results showed similar 3-year survival rates (55% vs. 57%) and no significant differences in disease-free survival or recurrence patterns. Trimodality therapy had higher rates of pathological response but also more adverse events, with no major differences in operative mortality or health-related quality of life outcomes. This study provides valuable insights into treatment approaches for this cancer type.
Like
Save
Share